Debes et al. confirmed a potential role of VEGF in risk of hepatocellular carcinoma, but they showed an alteration of baseline serum VEGF concentration in patients who developed HCC de novo, supporting the possible pre-existing increased VEGF level without a direct role of DAAs in liver cancer [50]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.